Table 1.
Patient demographics, admission vitals, disease severity, and catecholamine measurements in 35 PH patients. Medians (IQR) or n (%) are reported.
| IPAH | CTD-aPAH | CTEPH | ||
|---|---|---|---|---|
| (n = 12) | (n = 12) | (n = 11) | ||
| Demography | ||||
| Age | Years | 48.0 [39.8, 60.3] | 64.0 [47.0, 74.3] | 61.0 [51.5, 66.0] |
| Sex | Male, n (%) | 9 (75.0%) | 2 (16.7%) | 7 (63.6%) |
| Echocardiography | ||||
| TR | mmHg | 62.0 [48.3, 77.0] | 54.5 [47.8, 59.5] | 60.0 [50.0, 65.0] |
| Right heart catheterisation | ||||
| mPAP | mmHg | 54.0 [52.0, 63.0] | 45.5 [29.8, 51.3] | 42.0 [34.3, 48.0] |
| CI | L/min/m2 | 1.60 [1.25, 2.12] | 2.90 [2.38, 3.25] | 3.10 [2.90, 3.60] |
| PCWP | mmHg | 12.0 [11.0, 13.5] | 10.5 [7.75, 14.3] | 11.0 [10.0, 14.0] |
| PVR | Wood units | 13.5 [12.0, 15.6] | 6.45 [4.38, 9.75] | 5.20 [4.43, 6.38] |
| Laboratory parameter | ||||
| NT-proBNP | % max ULN | 271 [265, 919] | 158 [99.2, 745] | 148 [94.6, 420] |
| ELISA measurements | ||||
| Epinephrine | pg/mL | 14.4 [6.15, 25.0] | 14.0 [6.44, 31.1] | 16.9 [8.03, 27.5] |
| Norepinephrine | pg/mL | 236 [139, 425] | 386 [227, 461] | 458 [213, 578] |
| Outcome | ||||
| 6-min walking distance | m | 539 [473, 595] | 410 [345, 494] | 490 [416, 543] |
| WHO functional class | ||||
| I | Yes n (%) | 1 (8.3%) | 0 (0%) | 2 (18.2%) |
| II | Yes n (%) | 3 (25.0%) | 6 (50.0%) | 8 (72.7%) |
| III | Yes n (%) | 7 (58.3%) | 6 (50.0%) | 1 (9.1%) |
| IV | Yes n (%) | 1 (8.3%) | 0 (0%) | 0 (0%) |
CI, cardiac index; mPAP, mean pulmonary arterial pressure; NT-proBNP, N-terminal (NT)-pro brain natriuretic peptide (BNP); PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; TR, tricuspid regurgitation; ULN: upper limit of normal.